AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IS SUPERIOR TO ALEMTUZUMAB IN PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS AND SEVERE DISABILITY
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IS SUPERIOR TO ALEMTUZUMAB IN PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS AND SEVERE DISABILITY
Authors
Keywords
-
Journal
Multiple Sclerosis and Related Disorders
Volume -, Issue -, Pages 105096
Publisher
Elsevier BV
Online
2023-10-29
DOI
10.1016/j.msard.2023.105096
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party
- (2022) Maria Teresa Cencioni et al. Frontiers in Immunology
- Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
- (2021) Giacomo Boffa et al. NEUROLOGY
- The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge
- (2021) Iván Murrieta-Álvarez et al. Frontiers in Neurology
- aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
- (2021) Vivien Häußler et al. Annals of Clinical and Translational Neurology
- Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
- (2021) Tim Spelman et al. JAMA Neurology
- A real‐world study of alemtuzumab in a cohort of Italian patients
- (2021) Cinzia Valeria Russo et al. EUROPEAN JOURNAL OF NEUROLOGY
- Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis
- (2021) Richard K. Burt et al. JOURNAL OF NEUROLOGY
- Aggressive multiple sclerosis: a single center, real‐world treatment experience
- (2020) G. Boffa et al. EUROPEAN JOURNAL OF NEUROLOGY
- Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
- (2020) Brian Steingo et al. JOURNAL OF NEUROLOGY
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
- (2020) Ludwig Kappos et al. JAMA Neurology
- Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis
- (2020) N. Giedraitiene et al. Scientific Reports
- Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis
- (2019) Richard K. Burt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Highly active multiple sclerosis: An update
- (2019) Cindy Díaz et al. Multiple Sclerosis and Related Disorders
- Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms
- (2018) Tobias Alexander et al. JOURNAL OF AUTOIMMUNITY
- Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis
- (2018) Alexander Rae-Grant et al. NEUROLOGY
- Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale
- (2018) Dimitrios Karussis et al. IMMUNOLOGIC RESEARCH
- Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
- (2017) Ludwig Kappos et al. Multiple Sclerosis Journal
- Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
- (2017) Paolo A. Muraro et al. Nature Reviews Neurology
- Alemtuzumab CARE-MS I 5-year follow-up
- (2017) Eva Havrdova et al. NEUROLOGY
- Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
- (2017) Ludwig Kappos et al. Multiple Sclerosis Journal
- Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
- (2017) Eva Havrdova et al. Therapeutics and Clinical Risk Management
- NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
- (2016) Maria Pia Sormani et al. Multiple Sclerosis Journal
- NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
- (2016) Maria Pia Sormani et al. Multiple Sclerosis Journal
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
- (2011) J A Snowden et al. BONE MARROW TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More